AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|AAPL321.66-4.23 (-1.30%) ▼|ABBV256.92+3.62 (+1.43%) ▲|ABT100.75+0.18 (+0.18%) ▲|ACN138.74-1.35 (-0.96%) ▼|ADBE212.17-6.19 (-2.83%) ▼|AMAT562.80+8.88 (+1.60%) ▲|AMD539.69-12.64 (-2.29%) ▼|AMGN371.50+5.45 (+1.49%) ▲|AMT164.65-1.41 (-0.85%) ▼|AMZN233.66-11.19 (-4.57%) ▼|AVGO392.47-4.34 (-1.09%) ▼|AXP340.84-7.90 (-2.27%) ▼|BA209.23+0.58 (+0.28%) ▲|BAC61.28-0.34 (-0.55%) ▼|BKNG172.83-5.03 (-2.83%) ▼|BLK1,037.16-19.47 (-1.84%) ▼|BMY61.51+0.75 (+1.23%) ▲|BNY160.11-0.28 (-0.17%) ▼|BRK-B490.85+1.46 (+0.30%) ▲|C131.88-0.37 (-0.28%) ▼|CAT894.54+5.23 (+0.59%) ▲|CL90.08-1.55 (-1.69%) ▼|CMCSA21.92-1.60 (-6.80%) ▼|COF199.96-1.40 (-0.70%) ▼|COP120.20+1.41 (+1.19%) ▲|COST926.06-1.25 (-0.13%) ▼|CRM156.93-6.07 (-3.72%) ▼|CSCO112.76+0.55 (+0.49%) ▲|CVS106.89-0.53 (-0.49%) ▼|CVX194.42+1.44 (+0.75%) ▲|DE610.02+2.69 (+0.44%) ▲|DHR192.50+13.36 (+7.46%) ▲|DIS92.83-3.04 (-3.17%) ▼|DUK129.26+1.31 (+1.02%) ▲|EMR144.90+5.27 (+3.77%) ▲|FDX315.62-5.40 (-1.68%) ▼|GD381.79+8.63 (+2.31%) ▲|GE349.00+7.81 (+2.29%) ▲|GEV1,031.19+46.16 (+4.69%) ▲|GILD130.86+0.52 (+0.40%) ▲|GM80.67-1.46 (-1.78%) ▼|GOOG318.34-23.57 (-6.89%) ▼|GOOGL317.69-24.40 (-7.13%) ▼|GS1,074.72-23.48 (-2.14%) ▼|HD324.71-6.74 (-2.03%) ▼|HON246.27+13.28 (+5.70%) ▲|IBM206.65+0.88 (+0.43%) ▲|INTC100.23-2.39 (-2.33%) ▼|INTU281.53-2.94 (-1.03%) ▼|ISRG332.02-8.67 (-2.54%) ▼|JNJ259.27+3.64 (+1.42%) ▲|JPM349.90+1.69 (+0.49%) ▲|KO81.17-1.03 (-1.25%) ▼|LIN506.32-2.35 (-0.46%) ▼|LLY1,185.87+22.86 (+1.97%) ▲|LMT568.59+54.23 (+10.54%) ▲|LOW201.92-2.43 (-1.19%) ▼|LRCX319.78+0.49 (+0.15%) ▲|MA530.29-1.69 (-0.32%) ▼|MCD262.80-0.77 (-0.29%) ▼|MDLZ60.05-0.81 (-1.33%) ▼|MDT82.01+0.12 (+0.15%) ▲|META606.10-21.07 (-3.36%) ▼|MMM169.59-1.17 (-0.69%) ▼|MO72.08-0.09 (-0.12%) ▼|MRK130.48+3.01 (+2.36%) ▲|MS215.18-3.32 (-1.52%) ▼|MSFT381.58-8.76 (-2.24%) ▼|MU990.21+30.73 (+3.20%) ▲|NEE89.79+0.38 (+0.43%) ▲|NFLX68.89+0.36 (+0.53%) ▲|NKE40.99-1.22 (-2.89%) ▼|NOW91.94-3.52 (-3.69%) ▼|NVDA208.76-3.30 (-1.56%) ▼|ORCL120.04-5.80 (-4.61%) ▼|PEP134.95-0.70 (-0.52%) ▼|PFE25.01+0.19 (+0.77%) ▲|PG146.97-2.16 (-1.45%) ▼|PLTR123.37-1.20 (-0.96%) ▼|PM191.12-3.18 (-1.64%) ▼|QCOM171.11-4.52 (-2.57%) ▼|RTX209.16+14.28 (+7.33%) ▲|SBUX103.21-0.77 (-0.74%) ▼|SCHW101.61+0.81 (+0.80%) ▲|SO96.60+0.80 (+0.84%) ▲|SPG225.20-1.02 (-0.45%) ▼|T22.96-0.08 (-0.35%) ▼|TMO572.32+45.86 (+8.71%) ▲|TMUS170.42-20.52 (-10.75%) ▼|TSLA319.69-54.32 (-14.52%) ▼|TXN284.99-9.20 (-3.13%) ▼|UBER68.91-1.42 (-2.02%) ▼|UNH423.56-7.75 (-1.80%) ▼|UNP304.33+11.77 (+4.02%) ▲|UPS114.10-1.74 (-1.50%) ▼|USB63.33-1.14 (-1.77%) ▼|V351.60-1.82 (-0.52%) ▼|VZ43.82-0.47 (-1.06%) ▼|WFC86.19-0.23 (-0.27%) ▼|WMT108.40-0.93 (-0.85%) ▼|XOM156.89+2.44 (+1.58%) ▲|
20.7 C
New York
Friday, July 24, 2026

Tag: biotech company

newssourceFORcompanyinformationcontent1releasesmarket

Exo-Top, NurExone’s wholly owned U.S. Subsidiary, Enters Into Binding MOU For Naïve Exosome Distribution in Mexico

TORONTO, Ontario and HAIFA, Israel, June 25, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce today that its wholly owned U.S. subsidiary, Exo-Top Inc. (“Exo-Top”), has entered into a binding memorandum of understanding (the “MOU”) setting out the principal commercial terms for a proposed definitive distribution agreement (the “Definitive Agreement”) with ExoLyra LLC, which operates as an arm’s length third party (“ExoLyra”).

OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting

OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting

Clearmind Medicine Reaches Major Milestone, Completing Part A Treatment in FDA‑Regulated Phase I/II Trial

Vancouver, Canada, June 22, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

Insilico Medicine And SK Biopharmaceuticals Achieved AI-powered Drug Discovery Collaboration Worth Up to 2.5 Billion for Neuroimmune Disorders

CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a...

Polyrizon Advances NASARIX™ Development with Key Human Study to Characterize Nasal Residence Time and Support FDA Regulatory Pathway

New performance and characterization study in collaboration with leading European medical center marks a critical milestone in the validation of the NASARIX™ allergy blocker’s protective barrier function

Fedora Pharmaceuticals Expands Scientific Advisory Board with Appointment of Drs. Michael Dudley, Keith Micetich, and Jürgen Bulitta

Drs. Michael N. Dudley, Keith A. Micetich, and Jürgen B. Bulitta join advisory board of renowned infectious disease leaders at Fedora Pharmaceuticals.

Rakuten Medical Announces Executive Leadership Transition to Enhance Operational Execution and Organizational Discipline as a Global, Scalable Biotech Company

Minami Maeda appointed as CEO to drive faster, more focused execution toward U.S. commercial launchMickey Mikitani will continue to provide strategic direction and remains...

Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China

SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients...

PRESS RELEASE 

Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting

Assemblée Générale Mixte du 24 juin 2026 Modalités de mise à disposition des documents préparatoires à l’Assemblée

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Kazia Therapeutics Appoints James Levine as Chief Financial Officer

SYDNEY, June 2, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed...

Greywolf Therapeutics begins dosing of the first treatment to target the antigenic source of autoimmunity

Greywolf starts first trial of GRWD0715, aiming for a functional cure for autoimmunity by targeting its antigenic source.

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsBiotech company

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers